IFITM3, TLR3, and CD55 Gene SNPs and Cumulative Genetic Risks for Severe Outcomes in Chinese Patients with H7N9/H1N1 pdm09 Influenza

Journal of Infectious Diseases

Volumn 216, Issue 1, 2017, Pages 97-104

  Chan, Paul Kay Sheung ^a   Lee, Nelson ^a   Cao, Bin ^b   Ke, Changwen ^c   Lu, Hongzhou ^d   Hu, Yunwen ^e   Tam, Claudia Ha Ting ^a   Ma, Ronald Ching Wan ^a   Guan, Dawei ^c   Zhu, Zhaoqin ^e   Li, Hui ^b   Lin, Mulei ^f   Wong, Rity Y K ^a   Yung, Irene M H ^a   Hung, Tin Nok ^a   Kwok, Kirsty ^a   Horby, Peter ^g   Hui, David Shu Cheong ^a   Chan, Martin Chi Wai ^a  

^a Prince of Wales Hospital   (Hong Kong)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d FUDAN UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

^f SOUTHERN MEDICAL UNIVERSITY   (China)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

IFITM3; influenza; outcomes; SNP; TLR3.

Indexed keywords

DECAY ACCELERATING FACTOR; TOLL LIKE RECEPTOR 3; IFITM3 PROTEIN, HUMAN; MEMBRANE PROTEIN; RNA BINDING PROTEIN; TLR3 PROTEIN, HUMAN;

2009 H1N1 INFLUENZA; ADULT; ARTICLE; CD55 GENE; CHINESE; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIATION; HOMOZYGOSITY; HUMAN; IFITM3 GENE; IMMUNE RESPONSE GENE; INFLUENZA A (H7N9); INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SANGER SEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; TLR3 GENE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; GENETIC PREDISPOSITION; GENETICS; GENOTYPING TECHNIQUE; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H7N9); INFLUENZA, HUMAN; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTIGENS, CD55; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPING TECHNIQUES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA, HUMAN; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RNA-BINDING PROTEINS; TOLL-LIKE RECEPTOR 3;

EID: 85024497331     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix235     Document Type: Article

References (45)

1. WHO. Influenza at the human-animal interface. Summary and assessment, 22 November to 19 December 2016. http://www.who.int/influenza/human-animal- interface/Influenza-Summary-IRA-HA-interface-12-19-2016.pdf?ua=1. Accessed 10 January 2017.
2. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277-85.
3. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, et al; Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-19.
4. Lee N, Chan PK, Lui GC, et al. Complications and outcomes of pandemic 2009 influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis 2011; 203:1739-47.
5. Lee N, Leo YS, Cao B, et al. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur Respir J 2015; 45:1642-52.
6. Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 2012; 206:1359-66.
7. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol 2014; 14:315-28.
8. Lin TY, Brass AL. Host genetic determinants of influenza pathogenicity. Curr Opin Virol 2013; 3:531-6.
9. Horby P, Nguyen NY, Dunstan SJ, Baillie JK. An updated systematic review of the role of host genetics in susceptibility to influenza. Influenza Other Respir Viruses 2013; 7(Suppl 2):37-41.
10. Ciancanelli MJ, Abel L, Zhang SY, Casanova JL. Host genetics of severe influenza: from mouse Mx1 to human IRF7. Curr Opin Immunol 2016; 38:109-20.
11. Huang IC, Bailey CC, Weyer JL, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLOS Pathog 2011; 7:e1001258.
12. Bailey CC, Huang IC, Kam C, Farzan M. IFITM3 limits the severity of acute influenza in mice. PLOS Pathog 2012; 8:e1002909.
13. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLOS Pathog 2014; 10:e1004048.
14. Everitt AR, Clare S, Pertel T, et al.; GenISIS Investigators; MOSAIC Investigators. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 2012; 484:519-23.
15. Zhang YH, Zhao Y, Li N, et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun 2013; 4:1418.
16. Wang Z, Zhang A, Wan Y, et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci USA 2014; 111:769-74.
17. Yang X, Tan B, Zhou X, et al. Interferon-inducible transmembrane protein 3 genetic variant rs12252 and influenza susceptibility and severity: A meta-analysis. PLOS One 2015; 10:e0124985.
18. Wu W, Zhang W, Duggan ES, Booth JL, Zou MH, Metcalf JP. RIG-I and TLR3 are both required for maximum interferon induction by influenza virus in human lung alveolar epithelial cells. Virology 2015; 482:181-8.
19. Lee N, Wong CK, Hui DS, et al. Role of human Toll-like receptors in naturally occurring influenza A infections. Influenza Other Respir Viruses 2013; 7:666-75.
20. Esposito S, Molteni CG, Giliani S, et al. Toll-like receptor 3 gene polymorphisms and severity of pandemic A/H1N1/2009 influenza in otherwise healthy children. Virol J 2012; 9:270.
21. Chen C, Wang M, Zhu Z, et al. Multiple gene mutations identified in patients infected with influenza A (H7N9) virus. Sci Rep 2016; 6:25614.
22. Shirey KA, Lai W, Scott AJ, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 2013; 497:498-502.
23. Awomoyi AA, Rallabhandi P, Pollin TI, et al. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol 2007; 179:3171-7.
24. Zhou J, To KK, Dong H, et al. A functional variation in CD55 increases the severity of 2009 pandemic H1N1 influenza A virus infection. J Infect Dis 2012; 206:495-503.
25. Garcia-Etxebarria K, Bracho MA, Galan JC, et al.; CIBERESP Cases and Controls in Pandemic Influenza Working Group. No major host genetic risk factor contributed to A(H1N1)2009 influenza severity. PLOS One 2015; 10:e0135983.
26. Mills TC, Rautanen A, Elliott KS, et al. IFITM3 and susceptibility to respiratory viral infections in the community. J Infect Dis 2014; 209:1028-31.
27. Gaio V, Nunes B, Pechirra P, et al. Hospitalization risk due to respiratory illness associated with genetic variation at IFITM3 in patients with influenza A(H1N1) pdm09 infection: A case-control study. PLOS One 2016; 11:e0158181.
28. Zhu Z, Liu Y, Xu L, et al. Extra-pulmonary viral shedding in H7N9 avian influenza patients. J Clin Virol 2015; 69:30-2.
29. Ke C, Lu J, Wu J, et al. Circulation of reassortant influenza A(H7N9) viruses in poultry and humans, Guangdong Province, China, 2013. Emerg Infect Dis 2014; 20:2034-40.
30. Wang C, Yu H, Horby PW, et al. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis 2014; 58:1095-103.
31. Bai L, Gu L, Cao B, et al. Clinical features of pneumonia caused by 2009 influenza A(H1N1) virus in Beijing, China. Chest 2011; 139:1156-64.
32. Smieja M, Castriciano S, Carruthers S, et al. Development and evaluation of a flocked nasal midturbinate swab for self-collection in respiratory virus infection diagnostic testing. J Clin Microbiol 2010; 48:3340-2.
33. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-75.
34. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492-500.
35. Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza A and B infections. Clin Infect Dis 2013; 57:1511-9.
36. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445:881-5.
37. Ma RC, Tam CH, Wang Y, et al. Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. JAMA 2010; 304:881-9.
38. Assmann TS, Brondani Lde A, Bauer AC, Canani LH, Crispim D. Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus. Eur J Endocrinol 2014; 170:519-27.
39. Le Goffic R, Balloy V, Lagranderie M, et al. Detrimental contribution of the Tolllike receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLOS Pathog 2006; 2:e53.
40. Perales-Linares R, Navas-Martin S. Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology 2013; 140:153-67.
41. Salnikova LE, Smelaya TV, Moroz VV, Golubev AM, Rubanovich AV. Functional polymorphisms in the CYP1A1, ACE, and IL-6 genes contribute to susceptibility to community-acquired and nosocomial pneumonia. Int J Infect Dis 2013; 17:e433-42.
42. Tu X, Chong WP, Zhai Y, et al. Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection. J Infect 2015; 71:101-9.
43. Clemens EB, Grant EJ, Wang Z, et al. Towards identification of immune and genetic correlates of severe influenza disease in Indigenous Australians. Immunol Cell Biol 2016; 94:367-77.
44. Zuniga J, Buendia-Roldan I, Zhao Y, et al. Genetic variants associated with severe pneumonia in A/H1N1 influenza infection. Eur Respir J 2012; 39:604-10.
45. Simonsen L, Spreeuwenberg P, Lustig R, et al.; GLaMOR Collaborating Teams. Global mortality estimates for the 2009 influenza pandemic from the GLaMOR project: A modeling study. PLOS Med 2013; 10:e1001558.